Article Text

PDF
Both low-dose and micro-dose 17β-oestradiol reduced hot flushes

Statistics from Altmetric.com

G A Bachmann

Dr G A Bachmann, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA; gloria.bachmann@umdnj.edu

STUDY DESIGN

Design:

randomised, placebo-controlled trial.

Allocation:

concealed.*

Blinding:

blinded (patients, healthcare providers, and data collectors).*

STUDY QUESTION

Setting:

48 centres in the USA.

Patients:

425 healthy postmenopausal women ⩾40 years of age (mean age 53 y, mean time since menopause 9 y) who had an average of ⩾7 (mean 10) moderate or severe hot flushes per day for ⩾1 week during screening. Exclusion criteria included abnormal Pap test result, abnormal vaginal bleeding, and a history of thrombophlebitis or thromboembolic disorder.

Intervention:

transdermal patches delivering 0.023 mg/day 17β-oestradiol (E2) plus 0.0075 mg/day levonorgestrel (low-dose group, n = 145), 0.014 mg/day E2 (micro-dose group, n = 147), or no E2 (placebo group, n = 133).

Outcomes:

frequency and severity of hot …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.